[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Crinetics Pharmaceuticals (CRNX) reported an insider transaction by its Chief Medical and Development Officer. On November 3, 2025, the officer exercised 5,000 stock options at an exercise price of $16.89 per share and, on the same date, sold 4,900 shares at a volume‑weighted average price of $42.65 (price range $42.14–$43.09) and 100 shares at $43.27.

The sales were effected pursuant to a Rule 10b5‑1 trading plan adopted on May 21, 2025. Following the transactions, the officer directly beneficially owned 66,270 shares of common stock. Derivative securities beneficially owned following the transactions were 74,042 stock options. The option grant vests 25% on September 30, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued employment.

Insights

Insider trading compliance analyst

Pre‑planned Form 4: option exercise and same‑day sale totaling 5,000 shares.

The officer exercised $16.89 strike options for 5,000 shares on Nov 3, 2025 (code M) and sold 4,900 shares at a VWAP of $42.65 within a disclosed range, plus 100 shares at $43.27. The filing states the sale was executed under a Rule 10b5‑1 plan adopted on May 21, 2025.

Post‑trade holdings are listed as 66,270 common shares directly and 74,042 derivative securities (options). The plan designation indicates pre‑arranged execution mechanics, reducing discretionary timing concerns.

The vesting schedule notes 25% vested on Sep 30, 2023, with the balance vesting monthly over 36 months, contingent on continued employment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pizzuti Dana

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Med and Dev Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/03/2025		M		5,000	A	$16.89	71,270	D
Common Stock	11/03/2025		S(1)		4,900	D	$42.65(2)	66,370	D
Common Stock	11/03/2025		S(1)		100	D	$43.27(3)	66,270	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.89	11/03/2025		M			5,000	(4)	10/10/2032	Common Stock	5,000	$0	74,042	D

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.

2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $42.65 per share. The range of sale prices on the transaction date was $42.14 to $43.09. Detailed information on the exact number of shares can be obtained from the Issuer upon request.

3. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $43.27 per share for 100 shares.

4. The option is exercisable as follows: 25% of the shares subject to the option vested on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	11/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CRNX’s officer report on Form 4?

An exercise of 5,000 stock options at $16.89 and sales of 4,900 shares at a VWAP of $42.65 and 100 shares at $43.27 on November 3, 2025.

Was the CRNX insider sale under a 10b5-1 plan?

Yes. The filing states the sale was pursuant to a Rule 10b5‑1 trading plan adopted on May 21, 2025.

How many CRNX shares did the officer own after the transactions?

The officer directly beneficially owned 66,270 shares of CRNX common stock after the reported transactions.

What derivative holdings were reported after the CRNX transactions?

The filing lists 74,042 derivative securities (stock options) beneficially owned following the transactions.

What were the sale price details for the 4,900 CRNX shares?

They were sold at a volume‑weighted average price of $42.65, within a $42.14–$43.09 range on the transaction date.

What is the vesting schedule for the reported CRNX options?

25% vested on September 30, 2023, with the remainder vesting monthly over 36 equal installments, subject to continued employment.